RECRUITING

Pancreatic Cancer Early Detection Consortium

Talk to us

Conditions

Pancreas CancerPancreas CystPancreatic Ductal AdenocarcinomaGenetic Predisposition

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.

Official Title

Pancreatic Cancer Early Detection Consortium

Quick Facts

Study Start:2020-09-18
Study Completion:2030-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04970056

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 90 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.
  2. 2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family
  3. 3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family
  4. 4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+
  5. 5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+
  6. 6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+
  7. 1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+
  8. 2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family
  9. 3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member
  10. 1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other
  11. 2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11
  12. 3. Diagnosed ≤ age 45
  1. * Individuals not meeting the criteria above.

Contacts and Locations

Study Contact

Naveen Fawas, BS
CONTACT
7346654108
naveen.fawaz@arborresearch.org
John Graff, PhD
CONTACT
7346654108
john.graff@arborresearch.org

Principal Investigator

Diane Simeone, MD
STUDY_CHAIR
UC San Diego Moores Cancer Center

Study Locations (Sites)

Mayo Clinic Arizona
Phoenix, Arizona, 85054
United States
Honor Health Research Institute
Scottsdale, Arizona, 85258
United States
Providence Health and Services
Burbank, California, 91505
United States
City of Hope
Duarte, California, 91010
United States
UC San Diego Moores Cancer Center
La Jolla, California, 92093
United States
Cedars-Sinai Medical Center
Los Angeles, California, 90048
United States
UCLA Health
Los Angeles, California, 90095
United States
UC Irvine Health
Orange, California, 92868
United States
UC Davis
Sacramento, California, 95817
United States
University of California, San Francisco (UCSF)
San Francisco, California, 94143
United States
Yale University
New Haven, Connecticut, 06510
United States
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224
United States
University of Miami
Miami, Florida, 33136
United States
Moffitt Cancer Center
Tampa, Florida, 33612
United States
Emory University Hospital
Atlanta, Georgia, 30322
United States
Illinois CancerCare
Bloomington, Illinois, 61704
United States
University of Chicago Medicine
Chicago, Illinois, 60637
United States
NorthShore University HealthSystem
Evanston, Illinois, 60201
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
Umass Memorial Medical Center
Worcester, Massachusetts, 01655
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Beaumont/Corewell Health
Royal Oak, Michigan, 48073
United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198
United States
Hackensack Meridian Health
Hackensack, New Jersey, 07601
United States
Icahn School of Medicine At Mount Sinai
New York, New York, 10029
United States
Columbia University Irving Medical Center
New York, New York, 10032
United States
University of Rochester Medical Center
Rochester, New York, 14642
United States
White Plains Hospital
White Plains, New York, 10601
United States
The Ohio State University
Columbus, Ohio, 43210
United States
Oregon Health & Science University
Portland, Oregon, 97239
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
University of Pittsburgh Medical Center (Upmc)
Pittsburgh, Pennsylvania, 15232
United States
University of Tennessee Graduate School of Medicine
Knoxville, Tennessee, 37930
United States
The University of Texas Southwestern Medical Center
Dallas, Texas, 75390
United States
MD Anderson Center
Houston, Texas, 77030
United States
Intermountain Health
Saint George, Utah, 84790
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84112
United States
Inova Schar Cancer Institute
Fairfax, Virginia, 22031
United States
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298
United States
University of Washington
Seattle, Washington, 98195
United States

Collaborators and Investigators

Sponsor: Arbor Research Collaborative for Health

  • Diane Simeone, MD, STUDY_CHAIR, UC San Diego Moores Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-09-18
Study Completion Date2030-12-31

Study Record Updates

Study Start Date2020-09-18
Study Completion Date2030-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Pancreas Cancer
  • Pancreas Cyst
  • Pancreatic Ductal Adenocarcinoma
  • Genetic Predisposition